Tarsus Pharmaceuticals, Inc.
TARS
$68.90
$0.941.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.47% | 38.13% | 19.03% | -8.68% | 1.31% |
| Total Depreciation and Amortization | -3.70% | 1.55% | -1.52% | 6.48% | 52.11% |
| Total Amortization of Deferred Charges | 2.63% | 4.11% | 5.04% | 0.72% | 6.98% |
| Total Other Non-Cash Items | 24.10% | 62.50% | 16.07% | -5.06% | -5.57% |
| Change in Net Operating Assets | -29.77% | 218.18% | -756.28% | 66.65% | -172.42% |
| Cash from Operations | 5.88% | 162.13% | -42.30% | 6.90% | -156.38% |
| Capital Expenditure | -232.88% | -90.81% | -69.66% | -719.44% | 74.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,063.71% | 94.41% | -47.60% | 42.27% | -1,844.93% |
| Cash from Investing | 1,138.88% | 90.83% | -47.97% | 41.35% | -2,004.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -9.76% | 31.25% | -98.57% | 4,565.60% | 331.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -9.76% | 31.25% | -98.57% | 4,565.60% | 358.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 341.13% | 120.31% | -197.74% | 202.71% | -1,513.69% |